Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of Zeprumetostat in Healthy Chinese Males
NCT04335266Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zeprumetostat in lymphoma, peripheral T-cell lymphoma (PTCL), diffuse large B-cell lymphoma (DLBCL) and 1 more (2 arms), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration (Cmax) at Day 8 and Area Under the Curve (AUC) at Day 8. Started Aug 2019; status: completed.
02
Drugs
zeprumetostat
03
Conditions
lymphomaperipheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)solid tumor
Beyond the preview
Go deeper on NCT04335266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04335266.